GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 72, No. 8_Supplement ( 2012-04-15), p. 2869-2869
    Abstract: One of the major molecular players in cellular stress responses is the p53 tumor suppressor protein. The vast majority of the research of p53 activities upon DNA damage has focused on its cell autonomous functions, i.e. its ability to induce cell cycle arrest, DNA repair, apoptosis, autophagy, or senescence in a homogenous cell population. However, data on the impact of tumor cells on p53 activation in their neighboring cancer associated fibroblasts (CAFs) and also vice versa are still limited. We investigated p53 status and responses to the p53-activating drug cisplatin both in tumor cells and in their adjacent CAFs in intact tumor tissues derived from 28 individual lung cancer patients. For this, 200µm thick patient derived tissue slices were cultivated ex vivo in presence or absence of cisplatin for 72 hours. By comparing cultivated control slices with the corresponding tumor tissue material immediately fixed after surgery (pathological routine material) we could show that morphology and p53 staining pattern were highly preserved during cultivation. TP53 mutations were detected in 16 of the 28 cases (57.1%). Independent of their p53 mutation status, the tumor samples could be divided into 3 categories according to their p53 immunostaining characteristics in the tumor cell compartment: (I) tumor cells with constitutively low p53 protein which was accumulated upon cisplatin (12 cases, 7 with mutated p53); (II) tumor cells with constitutively high p53 and no further accumulation upon cisplatin (8 cases, 7 with mutated p53); (III) tumor cells with constitutively no detectable p53 and no accumulation upon cisplatin (8 cases, 2 with mutated p53). Importantly, regardless of the p53 mutation status of the tumor cell compartment we detected a CAF specific p53 accumulation and induction of the p53 target p21 selectively in category I tumors (i.e. tumor tissue samples characterized by p53 accumulation in the tumor cell compartment). In sharp contrast, tumor tissues with no detectable p53 accumulation in tumor cells (categories II and III) showed no p53 accumulation or p21 induction in their adjacent fibroblast compartment. Furthermore, a CAF specific induction of TUNEL positive cells in cisplatin treated samples (7 of 28 cases) was selectively observed in tumor tissues characterized by a parallel induction of tumor cell death. These data for the first time show a close correlation of p53 response in tumor cells and adjacent fibroblasts in intact lung tumor tissues from patient derived material indicating that tumor cells control molecular and functional responses of their neighborhood fibroblasts upon DNA damage. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2869. doi:1538-7445.AM2012-2869
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2012
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2010
    In:  Cancer Research Vol. 70, No. 8_Supplement ( 2010-04-15), p. 1425-1425
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 70, No. 8_Supplement ( 2010-04-15), p. 1425-1425
    Abstract: Cancer associated fibroblasts (CAFs) show a molecular and functional phenotype that is different from their normal counterparts (normal fibroblasts, NAFs). It is a well established phenomenon that these modified and activated fibroblasts possess permissive and promoting properties for epithelial tumor cells and therefore play a central role in tumor progression, metastasis, and probably also in sensitivity to antitumor agents. We asked whether CAFs could be reverted back pharmacologically to normal homeostasis by inhibiting PDGFR signalling. We therefore evaluated the efficacy of the FDA approved PDGFR inhibitor Dasatinib on proliferation and gene expression profile of CAF strains isolated from different lung carcinoma specimens. Dasatinib significantly reduced proliferation without inducing cell death in all 40 CAF strains investigated. Genome-wide microarray analysis of 9 CAF strains cultivated in presence or absence of Dasatinib identified 491 genes whose expression was significantly changed at least twofold. 104 of these encoded cell cycle related proteins with a great majority of 97 being down-regulated by Dasatinib. To determine the relevance of the differentially regulated genes in Dasatinib treated cells, we compared the Dasatinib expression signature to the previously described signatures of NAFs and CAFs derived from breast cancer patients (Sadlanova et al., 2008). Importantly, 102 of the 491 genes regulated by Dasatinib were also shown to be differentially expressed in CAFs versus NAFs. The expression of 72 of the genes we identified as down-regulated by Dasatinib was also reduced in NAFs compared to CAFs (p & lt;0.0001 in Fisher's exact analysis). In addition, 30 genes identified as up-regulated by Dasatinib were also found to be elevated in NAFs compared to CAFs (p & lt;0.0001 in Fisher's exact analysis). In summary, our data suggest that Dasatinib may reverse the cancer-activated phenotype of CAFs to a normal fibroblast like phenotype. Dasatinib treatment may therefore also reverse the tumor-promoting properties of CAFs. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1425.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2010
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Molecular Cancer, Springer Science and Business Media LLC, Vol. 9, No. 1 ( 2010-12)
    Abstract: Cancer associated fibroblasts (CAFs) play a critical role for growth, invasion, and metastasis of cancer. Therefore, targeting CAFs with small molecule inhibitors may be an attractive anti-tumor strategy. The current study aims to identify small molecule kinase inhibitors affecting CAF's growth and to characterize the biological effects of active compounds on primary CAFs from lung cancer. We screened two individual CAF strains for their sensitivity to a panel of 160 kinase inhibitors. Five kinase inhibitors were identified inhibiting more than 50% of the growth of both cell lines. Three of them were inhibitors of PDGFR at nanomolar concentrations. Therefore, we further tested the FDA approved PDGFR inhibitors Dasatinib, Nilotinib, Sorafenib, and Imatinib. All 37 CAF strains investigated were highly sensitive to Dasatinib at clinically relevant concentrations. Imatinib was slightly less effective, whereas the inhibitory effects of Nilotinib and Sorafenib were significantly less pronounced. We investigated the effect of Dasatinib on the CAF transcriptome by microarray analysis of 9 individual CAF strains. 492 genes were identified whose expression was changed at least twofold. 104 of these encoded cell cycle related proteins with 97 of them being downregulated by Dasatinib. The majority of regulated genes, however, were of diverse biological functions not directly related to proliferation. We compared this Dasatinib expression signature to previously described differential signatures of normal tissue associated fibroblasts (NAFs) and CAFs and to a signature of fibroblast serum response. There was a significant overlap between genes regulated by Dasatinib and serum repression genes. More importantly, of the 313 genes downregulated by Dasatinib 64 were also reduced in NAFs compared to CAFs. Furthermore, 26 of 179 genes identified as upregulated by Dasatinib were also found to be elevated in NAFs compared to CAFs. These data demonstrate that Dasatinib partially reverses the phenotype of CAFs to a normal fibroblast like phenotype. This is further supported by the finding that incubation of tumor cells with conditioned medium from CAFs pre-incubated with Dasatinib significantly reduced tumor cell proliferation, suggesting that Dasatinib partially reverses the CAF mediated tumor promoting effect. Therefore, targeting CAFs with Dasatinib represents a promising therapeutic principle.
    Type of Medium: Online Resource
    ISSN: 1476-4598
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2010
    detail.hit.zdb_id: 2091373-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 72, No. 22 ( 2012-11-15), p. 5824-5832
    Abstract: Current understanding of the p53 response is based mainly upon in vitro studies of homogeneous cell populations. However, there is little information on whether the same principles operate within heterogeneous tumor tissues that are comprised of cancer cells and other cell types, including cancer-associated fibroblasts (CAF). Using ex-vivo tissue cultures, we investigated p53 status and responses to cisplatin in tumor cells and CAFs from tissue specimens isolated from 32 lung cancer patients. By comparing cultivated tissue slices with the corresponding tumor tissues fixed immediately after surgery, we found that morphology, proliferation, and p53 staining pattern were preserved during cultivation. Unexpectedly, when CAFs were analyzed, p53 accumulation and induction of p21 was observed only in tumors with constitutively low p53 protein and accumulation upon cisplatin treatment. In contrast, in tumors with no p53 accumulation in cancer cells there was also no p53 accumulation or p21 induction in adjacent CAFs. Furthermore, induction of cisplatin-induced apoptosis in CAFs was selectively observed in tumors characterized by a parallel induction of cancer cell death. Our findings reveal an interdependence of the p53 response in cancer cells and adjacent CAFs within tumor tissues, arguing that cancer cells control the response of their microenvironment to DNA damage. Cancer Res; 72(22); 5824–32. ©2012 AACR.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2012
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...